## REMARKS

The Office Action and the cited and applied references have been carefully studied. No claim is allowed. Claims 20-26, 32, 33, 38, 39, and 42 presently appear in this application and define patentable subject matter warranting their allowance. Reconsideration and allowance are hereby respectfully requested.

Claims 20-26, 32, 33, 38, 39, 42 and 43 stand rejected under 35 U.S.C. §112, first paragraph, as lacking adequate written description and enablement for the full scope of the claimed subject matter. While applicants do not concede to this holding of lack of adequate written description and enablement, applicants have amended the claims and cancelled rejected claim 43 for reasons of business strategy and without prejudice, thereby obviating these rejections under §112, first paragraph.

Reconsideration and withdrawal of the 35 U.S.C. §112, first paragraph, rejections are therefore respectfully requested.

Claims 20, 21, 23, 24, 26, and 38 stand rejected under 35 U.S.C. §102(b) as being anticipated by Carrere et al. (1986).

Claims 20, 21, 23, 25, 26 and 29 stand rejected under 35 U.S.C. §102(b) as being anticipated by Geokas et al. (1979).

Claims 20-23, 42 and 43 stand rejected under 35 U.S.C. §102(b) as being anticipated by Chu et al. (1984).

Claims 20, 21, 23, 25, 26, 32, 33, 39 and 42 stand rejected under 35 U.S.C. §102(b) as anticipated by Iwaki et al. (1983).

Appln. No. 09/856,319 Amd. dated October 21, 2003 Reply to Office Action of July 25, 2003

Claims 20, 21, 23, 24, 25, 26, 33, 38 and 39 have been rejected under 35 U.S.C. §102(b) as being anticipated by Reseland et al. (1997).

Claim 22 has been rejected under 35 U.S.C. §103(a) as being unpatentable over Reseland et al. (1997).

The above prior art rejections are now obviated by the amendments to the claims which also obviate the §112, first paragraph, rejections. The claims as amended certainly cannot be construed as encompassing an antibody against any protein having serine protease activity. Accordingly, reconsideration and withdrawal of the rejection are therefore respectfully requested.

In view of the above, the claims comply with 35 U.S.C. §112 and define patentable subject matter warranting their allowance. Favorable consideration and early allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

Allen C. Yun Registration No. 37,971

ACY:pp

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528 G:\BN\A\Aoyb\Uemura5\PTO\amd OA 07-25-03.doc